Company AroCell AB

Equities

AROC

SE0003883990

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for AroCell AB

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 04:34:39 2024-04-29 am EDT			5-day change	1st Jan Change
0.372 ^SEK	0.00%		-1.59%	-14.87%

Apr. 18	Swedish Diagnostics Company AroCell Secures US Patent	MT
Feb. 22	AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.

Number of employees: 22

SEK in Million	2020	Weight	2021	Weight	Delta
Research and Development in Cell Biology and Medicine 100.0 %	0	100.0 %	12	100.0 %	+14,180.95%

SEK in Million	2020	Weight	2021	Weight	Delta
Sweden 100.0 %	0	100.0 %	12	100.0 %	+14,180.95%

Managers	Title	Age	Since
Anders Hultman CEO	Chief Executive Officer	50	18-11-30
Lars Jakobsson DFI	Director of Finance/CFO	67	-
Gustav Sten COO	Chief Operating Officer	-	18-12-31
Gunnar Steineck CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Kiran Kumar Jagarlamudi CTO	Chief Tech/Sci/R&D Officer	-	14-12-31
Alona Nyberg IRC	Investor Relations Contact	-	18-12-31
Gunnar Wahlberg SAM	Sales & Marketing	54	20-12-31
Tina Yang PRN	Corporate Officer/Principal	-	16-12-31
Peter Lowendahl LAW	General Counsel	-	18-12-31
Filip Fogdestam PRN	Corporate Officer/Principal	-	13-12-31

Members of the board	Title	Age	Since
Johan Erik Häggblad CHM	Chairman	65	21-12-31
Charlotta Ljungqvist BRD	Director/Board Member	63	21-04-30
Clas Runnberg BRD	Director/Board Member	72	22-12-31
Gunnar Steineck CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Max Pihlqvist BRD	Director/Board Member	37	21-12-31
Eva Nordström BRD	Director/Board Member	54	19-12-31
Agneta Tufvesson Alm BRD	Director/Board Member	-	21-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	230,361,066	102,183,486 ( 44.36 %)	0	44.36 %

Name	Equities	%	Valuation
Arvernus Capital AG 0.1912 %	440,492	0.1912 %	15 162 kr

AroCell AB

Karlsbodavägen 39

168 67, Bromma Stockholm

+46 87 99 67 50

http://www.arocell.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROCELL AB	-14.87%	7.82M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.37%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research